Elite Pharmaceuticals, Inc. ELTP OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

65/100

2/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Elite Pharmaceuticals, Inc. (ELTP) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 61/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

65/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

PAST

75/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

39/100

→ Income

✓

GROWTH

100/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — ELTP

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio4.83

EV/EBITDA0.0

Per Share Data

EPS (TTM)$0.00

Book Value / Share$0.00

Revenue / Share$0.08

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$0.00	$12.5M	$-683.01K	-5.5%
2017	$-0.01	$9.64M	$3.81M	39.5%
2018	$0.00	$7.46M	$-3.67M	-49.2%
2019	$-0.01	$7.57M	$-9.28M	-122.6%
2020	$0.00	$17.99M	$-2.24M	-12.5%
2021	$0.01	$25.38M	$5.09M	20%
2022	$0.01	$32.26M	$8.9M	27.6%
2023	$4.35	$34.16B	$4.41B	12.9%
2024	$0.02	$56.63M	$20.11M	35.5%
2025	$0.00	$84.04M	$-4.31M	-5.1%